Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C

Antonio Gasbarrini, Matteo Ruggeri, Rosa Anna Bruno, Calogero Cammà, Salvatore Petta, Giuseppe Cabibbo, Marco Enea, Raffaele Bruno, Vincenza Capursi, Alfredo Alberti, Antonio Craxì

Risultato della ricerca: Contributo in rivistaArticolo in rivista

37 Citazioni (Scopus)

Abstract

Randomised controlled trials (RCTs) show that triple therapy (TT) with peginterferon alfa, ribavirin, and boceprevir (BOC) or telaprevir (TVR) is more effective than peginterferon-ribavirin dual therapy (DT) in the treatment of genotype 1 (G1) chronic hepatitis C (CHC) patients with previous relapse (RR), partial response (PAR), and null-response (NR). We assess the cost-effectiveness of TT compared to no therapy in the treatment of patients previously treated with G1 CHC.
Lingua originaleEnglish
pagine (da-a)658-666
Numero di pagine9
RivistaJournal of Hepatology
Volume59
DOI
Stato di pubblicazionePubblicato - 2013

Keywords

  • BOC
  • Boceprevir
  • CHC
  • Cost-effectiveness
  • DT
  • G1
  • ICER
  • NR
  • PAR
  • PI
  • PegIFN
  • RBV
  • RR
  • TVR
  • Telaprevir
  • boceprevir
  • chronic hepatitis C
  • dual therapy
  • genotype 1
  • incremental cost-effectiveness ratio
  • non-response
  • partial response
  • pegylated interferon
  • protease inhibitors
  • relapse
  • ribavirin
  • telaprevir

Fingerprint

Entra nei temi di ricerca di 'Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C'. Insieme formano una fingerprint unica.

Cita questo